US 12447128

US Patent 12447128B2, titled "Formulations of enzalutamide," was issued on October 21, 2025, from an application filed on November 11, 2022. The patent is currently assigned to Astellas Pharma Inc and Medivation Prostate Therapeutics LLC. The inventors are Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, and Atsushi Kanbayashi.

Abstract:
The patent describes solid formulations of enzalutamide, specifically focusing on pharmaceutical compositions that include amorphous enzalutamide within a solid dispersion with at least one polymer. The disclosure also covers methods for manufacturing these formulations and compositions, and their intended use.

Overview of Independent Claims:

• Independent Claim 1: This claim describes a pharmaceutical composition containing a solid dispersion. The solid dispersion comprises enzalutamide and at least one polymer, where the enzalutamide is at least 60% amorphous. When this composition is given orally to a group of 24 or more humans at a 160 mg dose, it must result in a mean area under the plasma enzalutamide concentration-time curve (AUC 0-7 days) greater than 150 µg·hr/ml. Additionally, the solid dispersion must contain less than 30% by weight of lipophilic microphase-forming materials.
• Independent Claim 11: This claim outlines a manufacturing method for a solid dispersion containing enzalutamide and at least one polymer. The method involves dissolving both enzalutamide and the polymer(s) in a common solvent to create a solution, then using spray drying to remove the solvent, thus forming the solid dispersion. The resulting enzalutamide in the solid dispersion must be at least 60% amorphous, and the solid dispersion must contain less than 30% by weight of lipophilic microphase-forming materials.
• Independent Claim 17: Similar to Claim 1, this claim describes a pharmaceutical composition with a solid dispersion of at least 60% amorphous enzalutamide and at least one polymer. This composition, when administered orally to a cohort of 24 or more humans at a 160 mg dose, must achieve a mean maximum plasma enzalutamide concentration (Cmax) greater than 2 µg/ml. The solid dispersion also has the same limitation of containing less than 30% by weight of lipophilic microphase-forming materials.

Litigation Search:
A direct search of the CAFC 2026 dockets for patent number US12447128B2 did not immediately return specific case filings or scheduled cases directly mentioning this patent. However, the Google Patents information for US12447128B2 indicates that its "Family has litigation" and notes that the "First worldwide family litigation filed" occurred, with a link to a Darts-ip.com entry for family 49231627. The current status of the patent is "Active," with an anticipated expiration date of September 11, 2033.

My search for litigation specifically involving US patent 12447128 did not yield any direct results detailing known lawsuits, plaintiffs, defendants, jurisdictions, case numbers, filing dates, or outcomes. While the Google Patents page for US12447128B2 indicates "Family has litigation" and links to Darts-ip, I cannot directly access specific case details via that link.

The search results did indicate that the current assignees, Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC, are involved in various patent litigations concerning other patent numbers related to their products, such as Xtandi® (enzalutamide) and Myrbetriq® (mirabegron). However, none of these specifically list US patent 12447128 as being litigated. For example:

• Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC are plaintiffs in cases involving US Patent No. 7,709,517 and US Patent No. 12,066,689.
• Astellas Pharma Inc. is involved in litigation concerning Myrbetriq® patents, including US10842780, US11707451, US12059409, and US12097189.

Therefore, based on the conducted search, no specific litigation involving US patent 12447128 has been identified.

Proceedings overview

There is no PTAB activity on file for US patent 12447128. This suggests that the patent has not yet been challenged in an AIA trial proceeding, which could indicate a less hardened defensive posture if faced with assertion.

Strategic summary

As there are no PTAB proceedings on file for US patent 12447128, all claims of the patent remain untested by AIA trial proceedings. This means there are no canceled or sustained claims through IPR, PGR, or CBM. Consequently, there is no estoppel landscape established by the PTAB regarding this patent, and all prior-art grounds remain available for potential challenges. The absence of PTAB activity also means there are no patterns to observe regarding petitioner behavior, patent owner's appeal aggressiveness, or involvement of defensive aggregators like Unified Patents.

Recommended next steps

If you are a defendant facing assertion of US patent 12447128, the absence of PTAB activity means that all claims are currently presumed valid from an AIA trial perspective. An IPR, PGR, or CBM could be considered as a defense strategy, as the patent has not yet undergone the scrutiny of these proceedings.

Inventors

• Douglas Alan Lorenz (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Sanjay Konagurthu (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Randy J. Wald (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Jason A. Everett (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Sheila Matz (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Yuuki Takaishi (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Toshiro Sakai (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Ryousuke Irie (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Shinsuke Oba (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Hiroyasu Toyota (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Koji Nishimura (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
• Atsushi Kanbayashi (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)

Original assignee

Astellas Pharma Inc and Medivation Prostate Therapeutics LLC are listed as the original co-assignees on the patent.

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company that develops, manufactures, and sells pharmaceutical products. They ship products embodying the claims, specifically XTANDI® (enzalutamide) soft capsules. Medivation Prostate Therapeutics LLC appears to be a subsidiary of Medivation, Inc., which was acquired by Pfizer in 2016 and was focused on developing therapies for prostate cancer. Given the acquisition of Medivation by Pfizer, Medivation Prostate Therapeutics LLC is likely no longer an independent operating entity and its assets, including patents, would have been integrated into Pfizer's portfolio.

Assignment timeline

The USPTO Patent Assignment Search for US patent 12447128 currently shows no recorded assignments. This indicates that the ownership of the patent remains with the original assignees, Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC, as granted.

Timeline diagram

timeline
    title Ownership of US 12447128
    2012 : Priority date
    2022 : Application filed by Astellas Pharma Inc, Medivation Prostate Therapeutics LLC
    2025 : Granted to Astellas Pharma Inc, Medivation Prostate Therapeutics LLC

NPE / troll-pattern signals

1. Shell-entity transfer — not present
2. Known asserter in the chain — not present
3. Repeat correspondent across the chain — not present
4. Cascading transfers — not present
5. Pre-litigation transfer — not present
6. Bankruptcy fire-sale — unclear (Medivation, LLC was acquired by Pfizer, which means its assets, including patents, would have transferred. However, this is an acquisition, not a bankruptcy fire-sale of Astellas Pharma Inc. The specific status of Medivation Prostate Therapeutics LLC's patent holdings post-acquisition isn't explicitly detailed as a separate transfer event in the assignment records for this patent.)
7. Privateering — not present
8. Defensive aggregator (anti-NPE) — not present

Verdict

Insufficient data
There are no recorded assignments for US patent 12447128 in the USPTO Assignment Center. Without any transfer records, it is not possible to identify any NPE or patent-troll patterns. The patent remains with the original co-assignees, Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC, as of the grant date (2025-10-21).

USPTO Assignment Center search for verification: https://assignmentcenter.uspto.gov/

To identify the most relevant prior art for US patent 12447128, I will examine the patent's cited references. Based on the patent text provided, the following prior art documents are explicitly mentioned:

• U.S. Pat. No. 7,709,517 (US7709517B2): This patent is cited multiple times in US12447128B2. It discloses diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing and using them to treat hormone-refractory prostate cancer. Enzalutamide's chemical name and structural formula are mentioned in relation to this patent. US7709517B2 also discusses pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable carrier, along with methods for treating hyperproliferative disorders like hormone-refractory prostate cancer. The US12447128B2 patent states that enzalutamide is provided commercially as a soft capsule (XTANDI®) and that US7709517B2 discloses the use of enzalutamide as an agent for treating castration-resistant prostate cancer.

  • Publication/Filing Date: The priority date for US7709517B2 is May 13, 2005, and it was granted on May 4, 2010.
  • Brief Description: This patent introduces diarylhydantoin compounds (including diarylthiohydantoins like enzalutamide) as androgen receptor antagonists, their synthesis, and their use in treating hormone-refractory prostate cancer. It also covers pharmaceutical compositions containing these compounds.
  • Potential Anticipation (35 U.S.C. § 102): US7709517B2 potentially anticipates claims in US12447128B2 related to the compound enzalutamide itself, its chemical structure, its use in treating prostate cancer, and basic pharmaceutical compositions (e.g., comprising enzalutamide and a pharmaceutically acceptable carrier), as it is the foundational patent disclosing enzalutamide. However, US12447128B2 focuses on formulations of enzalutamide, specifically amorphous forms and solid dispersions, which are not explicitly detailed in US7709517B2 as its primary focus. For instance, US12447128B2 notes that enzalutamide in US7709517B2 exists as a colorless crystal, contrasting with the amorphous forms claimed in 12447128.

• US2002/0031547: This patent literature reports a sparingly soluble compound held on a gel-forming water-soluble polymer as a solid dispersion, where a salt substance is included to improve disintegration time and dissolution profile.

  • Publication/Filing Date: While the exact filing date isn't immediately available from the provided text, the publication date is listed as 2002/0031547.
  • Brief Description: Discloses solid dispersions of sparingly soluble compounds with gel-forming water-soluble polymers, incorporating salt substances for improved disintegration and dissolution.
  • Potential Anticipation (35 U.S.C. § 102): This patent potentially anticipates claims related to general concepts of solid dispersions for sparingly soluble compounds, the use of gel-forming water-soluble polymers (like HPMC or HPC mentioned in the context of this reference in US12447128B2's background), and enhancing dissolution properties. However, it does not specifically mention enzalutamide.

• US2002/0009494: This publication reports the use of hydroxypropylmethylcellulose acetate succinate (HPMCAS) in a pharmaceutical composition of a sparingly soluble compound, prepared by a spray drying method, to improve aqueous solubility and/or bioavailability.

  • Publication/Filing Date: The publication date is January 26, 2001.
  • Brief Description: Focuses on using HPMCAS in spray-dried solid amorphous dispersions of sparingly soluble drugs to enhance aqueous solubility and bioavailability. It also mentions that such dispersions can be prepared by forming a homogeneous solution or melt of the drug and matrix material followed by solidifying the mixture by cooling or solvent removal.
  • Potential Anticipation (35 U.S.C. § 102): This patent is highly relevant as it describes amorphous solid dispersions of sparingly soluble drugs using a specific polymer (HPMCAS) and a specific method of preparation (spray drying) to improve bioavailability, directly aligning with key aspects of US12447128B2. It could potentially anticipate claims in US12447128B2 related to the general concept of amorphous solid dispersions of poorly soluble drugs with HPMCAS, prepared via spray-drying for improved solubility and bioavailability. Claims related to compositions comprising amorphous enzalutamide and HPMCAS, and methods of making them via spray-drying, would need to demonstrate novelty over the general teachings of this reference.

• U.S. Pat. No. 7,611,630 B2: This patent is referenced for further details on the membrane permeation test.

  • Publication/Filing Date: The provided text does not explicitly state the publication or filing date for US7611630B2, only its reference.
  • Brief Description: Provides details on a "membrane permeability test" used to assess the capacity of a dispersion to resupply free drug in solution.
  • Potential Anticipation (35 U.S.C. § 102): This patent describes an analytical method and would not anticipate compositional or method claims of US12447128B2. It is cited as a methodology reference.

In summary, US7709517B2 establishes the active pharmaceutical ingredient (enzalutamide) and its therapeutic use. US2002/0031547 and US2002/0009494 are particularly pertinent as they deal with the broader concepts of solid dispersions and methods for improving drug solubility and bioavailability, which are central to the claims of US12447128B2. US2002/0009494, specifically mentioning HPMCAS and spray-drying for sparingly soluble compounds, appears to be the most relevant in terms of potentially anticipating the formulation aspects of US12447128B2.

Obviousness Analysis of US Patent 12447128

This analysis considers the obviousness of US patent 12447128 under 35 U.S.C. § 103, based on the prior art references explicitly cited within the patent's "Definitions" section.

Background of the Invention

US patent 12447128 addresses the challenge of formulating enzalutamide, an androgen receptor signaling inhibitor used for treating castration-resistant prostate cancer. The commercial product, XTANDI®, is a soft capsule containing liquid enzalutamide, requiring patients to take four 40 mg capsules daily for a 160 mg dose. The patent aims to provide a "suitable tablet of reasonable size" comprising the prescribed amount of enzalutamide, with "suitable and advantageous solubility and/or dissolution stability and absorption," as a more convenient alternative to soft capsules.

The patent's solution centers on solid formulations comprising amorphous enzalutamide in a solid dispersion with at least one concentration-enhancing polymer. These compositions are prepared by methods such as spray-drying or hot-melt extrusion, and are characterized by enhanced dissolution (e.g., higher Maximum Drug Concentration (MDC) and Area Under The Curve (AUC) in in vitro tests) and improved oral bioavailability in vivo. Preferred polymers include hydroxypropylmethylcellulose acetate succinate (HPMCAS), and preferred manufacturing methods include spray-drying.

Identified Prior Art

The US patent 12447128 explicitly references the following as prior art or relevant background:

1. U.S. Pat. No. 7,709,517: Discloses enzalutamide, its chemical structure, and its use as an agent for treating various cancers, including castration-resistant prostate cancer. It also describes crystalline enzalutamide.
2. US2002/0031547: Reports a solid dispersion of a sparingly soluble compound with a gel-forming water-soluble polymer (e.g., hydroxypropyl methylcellulose or hydroxypropylcellulose) to improve disintegration time and dissolution profile.
3. US2002/0009494: Discloses the use of hydroxypropylmethylcellulose acetate succinate (HPMCAS) in a pharmaceutical composition comprising a sparingly soluble compound, prepared by a spray drying method, to improve aqueous solubility and/or bioavailability.

Obviousness Analysis (35 U.S.C. § 103)

A person having ordinary skill in the art (POSA) in pharmaceutical formulation and drug delivery would be familiar with techniques to enhance the solubility and bioavailability of poorly soluble drugs, including the use of amorphous solid dispersions and various excipients.

Combination of U.S. Pat. No. 7,709,517 and US2002/0009494:

This combination provides strong grounds for an obviousness challenge to the central aspects of US patent 12447128.

• U.S. Pat. No. 7,709,517 establishes enzalutamide as a known drug with therapeutic utility. The problem statement in US12447128 itself indicates that enzalutamide, in its commercially available form, requires multiple liquid-filled capsules, implying a need for improved solid formulations. This strongly suggests that enzalutamide is a sparingly soluble compound, which would motivate a POSA to seek improved formulations.
• US2002/0009494 directly teaches the use of hydroxypropylmethylcellulose acetate succinate (HPMCAS) in a pharmaceutical composition comprising a sparingly soluble compound, prepared by a spray drying method, to improve aqueous solubility and/or bioavailability.

Motivation to Combine:
A POSA, tasked with developing a more convenient, effective solid oral dosage form for enzalutamide (known from '517), would immediately recognize the challenges associated with its likely poor aqueous solubility (inferred from the commercial liquid capsule formulation). The explicit teachings of US2002/0009494 provide a clear and direct motivation to combine the known drug enzalutamide with the specific polymer HPMCAS and the spray-drying method. The '494 publication precisely addresses the goal of improving aqueous solubility and bioavailability for sparingly soluble compounds, which aligns perfectly with the stated objective of US12447128.

Reasonable Expectation of Success:
Given the explicit teaching in US2002/0009494 that HPMCAS and spray-drying "improve aqueous solubility and/or bioavailability" for sparingly soluble compounds, a POSA would have a reasonable expectation of success in achieving these improvements for enzalutamide. It is well-established in the art that spray-drying a poorly soluble drug with a polymer often results in an amorphous solid dispersion, which is known to enhance dissolution rates compared to crystalline forms. The particular selection of HPMCAS is further supported by US12447128 itself, which describes HPMCAS as a "particularly desirable" and "concentration-enhancing polymer" that "performs particularly well." The specific quantitative enhancements in MDC, AUC, and Cmax, while perhaps significant, would be expected outcomes and/or achievable through routine optimization by a POSA following this established path. The goal of a single, higher-dose tablet would also be a natural consequence of achieving improved solubility and bioavailability, enabling higher drug loading per unit.

Addressing Arguments Against Obviousness:
US12447128 states that "Solubilization of a specific drug depends on its chemical structure and physical properties, therefore, whether any particular polymer will solubilize a specific drug is not necessarily predictable." While this general statement is true, the unpredictability argument is considerably weakened by the highly specific and relevant teaching of US2002/0009494. A POSA is not blindly experimenting with "any particular polymer" but is instead guided by a prior art reference that specifically identifies HPMCAS and spray-drying as effective for solving the very problem of enhancing solubility and bioavailability for sparingly soluble compounds.

Conclusion

Based on the combination of U.S. Pat. No. 7,709,517 and US2002/0009494, the claims of US patent 12447128 directed to an amorphous solid dispersion of enzalutamide with HPMCAS, prepared by spray-drying to improve aqueous solubility and/or bioavailability, would likely be considered obvious to a person having ordinary skill in the art. The motivation to combine these references is clear: to address the known solubility challenges of enzalutamide and develop a more convenient solid oral dosage form, utilizing a proven technique for sparingly soluble drugs that explicitly mentions the specific polymer and manufacturing method. The expectation of success in achieving improved solubility and bioavailability would be reasonable.

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) can extend the term of a U.S. patent to compensate for certain delays caused by the USPTO during the examination process. These delays include failing to: issue a first office action or notice of allowance within 14 months of filing; respond to an applicant's reply within four months; act on an appeal decision within four months; or issue a patent within four months of the issue fee payment. Additionally, PTA is granted if the application is pending for more than three years, excluding applicant-caused delays.

The Google Patents page for US12447128B2 does not explicitly state any Patent Term Adjustments. To determine the exact PTA, a detailed review of the patent's prosecution history in USPTO Patent Center would be necessary.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is available for patents on certain human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products to restore time lost during the regulatory review process for premarket government approval. The extension is limited to a maximum of five years, and the total patent life with a PTE cannot exceed 14 years from the date of FDA approval. Only one patent can be extended per regulatory review period for a given product.

The Google Patents page for US12447128B2 does not explicitly state any Patent Term Extensions. Given that enzalutamide (marketed as XTANDI®) is a drug, this patent could be eligible for PTE. However, a specific application for PTE would need to be filed and approved by the USPTO in conjunction with the FDA.

Continuation Applications, Divisional Applications, and Related Family Members

The Google Patents page for US12447128B2 lists the following related application numbers:

• US17/985,220 (Application number for US12447128B2 itself)
• US202217985220A (Another format for the application number)
• US20230122911A1 (Other version / publication number)

The patent text explicitly states that US12447128B2 claims priority to US17/985,220. In general, for applications filed on or after June 8, 1995, a patent granted on a continuation, divisional, or continuation-in-part application will have a term that ends twenty years from the filing date of the earliest application for which a benefit is claimed.

Projected Expiration Date

The "Prior art date" for US12447128B2 is September 11, 2012, and the "Filing date" of the application is November 11, 2022. The "Publication date" is October 21, 2025. The Google Patents page for US12447128B2 indicates an "Anticipated expiration" date of September 11, 2033.

The general rule for utility patents filed on or after June 8, 1995, is that the patent term begins on the date the patent issues and ends 20 years from the date on which the application was filed, or 20 years from the earliest filing date if it claims priority to an earlier application. The anticipated expiration date of September 11, 2033, aligns with 20 years from the "Prior art date" of September 11, 2012, which the patent likely claims as its earliest effective filing date for term calculation purposes. Without specific information on PTA or PTE from the USPTO official records, the anticipated expiration date provided by Google Patents is the most reliable current estimate.

Defensive Disclosure: Formulations of Enzalutamide (US12447128)

This document outlines derivative variations of the inventions claimed in US Patent 12447128 ("Formulations of enzalutamide"), intended for defensive publication. The goal is to establish prior art that renders future incremental improvements by competitors obvious or non-novel, specifically targeting the core claims related to amorphous enzalutamide solid dispersions, their manufacturing, and performance characteristics.

---

Derivative Variations

1. Material & Component Substitution

Derivative 1.1: Polymer Blend Amorphous Dispersion

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a polymer blend comprising hydroxypropyl methylcellulose acetate succinate (HPMCAS) and a thermally stable, water-soluble, non-ionic cellulosic polymer such as hypromellose (HPMC) at a weight ratio of 2:1 (HPMCAS:HPMC). The enzalutamide loading in the total polymer matrix is 60% w/w. This blend is prepared by co-dissolving enzalutamide, HPMCAS-M grade (e.g., Shin-Etsu AQOAT® HPMCAS-MG), and HPMC E5LV (e.g., Dow Methocel™ E5 LV) in a common solvent system of acetone:ethanol (1:1 v/v) at a concentration of 5% w/v total solids. The solution is then spray-dried using a laboratory-scale spray dryer with an inlet temperature of 90°C, a solvent feed rate of 25 mL/min, and an atomizing airflow of 0.7 bar. The resulting amorphous solid dispersion exhibits enhanced physical stability and dissolution performance compared to single-polymer systems, achieving a mean AUC 0-7 days greater than 150 µg·hr/ml at a 160 mg oral dose in humans and containing less than 30% by weight of lipophilic microphase-forming materials. The HPMC contributes to improved processability and matrix integrity, while HPMCAS maintains supersaturation.

graph TD
    A[Enzalutamide (API)] --> C{Dissolve in Common Solvent}
    B1[HPMCAS-M Polymer] --> C
    B2[HPMC E5LV Polymer] --> C
    C --> D[Homogeneous Solution]
    D --> E{Spray Drying}
    E --> F[Amorphous Solid Dispersion (ASD)]
    F --> G[Composition (Tablet/Capsule)]
    G --> H{Oral Administration}
    H --> I[Enhanced AUC/Cmax in vivo]

Derivative 1.2: Mesoporous Silica Carrier for Amorphous Enzalutamide

Enabling Description:
A pharmaceutical composition comprising enzalutamide (at least 60% amorphous) adsorbed onto a mesoporous silica carrier (e.g., SBA-15 or MCM-41 with pore size 2-10 nm) and subsequently encapsulated within a polymer matrix of polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA64). Enzalutamide is loaded into the mesoporous silica via incipient wetness impregnation from an ethanolic solution, followed by solvent evaporation to yield amorphous enzalutamide within the silica pores. This drug-loaded silica is then blended with PVP-VA64 powder at a 1:1 (w/w) ratio (drug-loaded silica:polymer) and processed via hot-melt extrusion at 150°C to form a final solid dispersion. The mesoporous silica acts as an inert scaffold for stabilizing the amorphous drug, and the polymer provides concentration enhancement and maintains stability. The final formulation, once milled, maintains enzalutamide in an amorphous state, achieves a mean Cmax greater than 2 µg/ml at a 160 mg oral dose, and contains less than 30% lipophilic microphase-forming materials.

graph TD
    A[Enzalutamide Solution] --> B{Impregnate Mesoporous Silica (SBA-15)}
    B --> C[Evaporate Solvent]
    C --> D[Amorphous Enzalutamide in Silica Pores]
    D --> E{Blend with PVP-VA64 Polymer}
    E --> F{Hot-Melt Extrusion (HME)}
    F --> G[SDD with Silica Carrier]
    G --> H[Composition (Milled Powder)]
    H --> I{Oral Administration}
    I --> J[Enhanced Cmax in vivo]

Derivative 1.3: Biodegradable Polymer Dispersion for Sustained Release

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a biodegradable polyester polymer, specifically poly(lactic-co-glycolic acid) (PLGA) with a lactic:glycolic acid ratio of 75:25 and a molecular weight of 30-60 kDa. The solid dispersion is prepared by co-dissolving enzalutamide and PLGA in a common solvent (e.g., dichloromethane) and forming microparticles via emulsion-solvent evaporation. The solution is emulsified in an aqueous phase containing a stabilizer (e.g., polyvinyl alcohol), followed by solvent removal to yield amorphous enzalutamide-PLGA microparticles. These microparticles provide sustained release capabilities in addition to enhanced solubility due to the amorphous state, suitable for extended dosing intervals. The resulting solid dispersion maintains amorphous enzalutamide, delivers an AUC 0-7 days greater than 150 µg·hr/ml, and is formulated with less than 30% by weight of lipophilic microphase-forming materials, potentially enabling reduced frequency dosing.

graph TD
    A[Enzalutamide] --> C{Co-dissolve in DCM}
    B[PLGA Polymer] --> C
    C --> D[DCM Solution]
    D --> E{Emulsify in Aqueous PVA}
    E --> F[Emulsion Droplets]
    F --> G{Solvent Evaporation}
    G --> H[Amorphous Enzalutamide-PLGA Microparticles]
    H --> I[Composition (Capsule/Injection)]
    I --> J{Administration}
    J --> K[Sustained Release & Enhanced AUC]

Derivative 1.4: Cryo-Milled Amorphous Enzalutamide with a Poloxamer Matrix

Enabling Description:
A pharmaceutical composition comprising enzalutamide (at least 60% amorphous) and a poloxamer, specifically Poloxamer 407 (Kolliphor® P 407). Enzalutamide is micronized via cryogenic milling at liquid nitrogen temperatures to induce amorphicity while minimizing degradation. The cryo-milled amorphous enzalutamide powder is then hot-melt extruded with Poloxamer 407 at a 1:2 (enzalutamide:Poloxamer) ratio at a temperature of 80°C, forming a eutectic or solid solution. Poloxamer 407 acts as both a solid dispersion matrix and a surfactant, ensuring rapid wetting and solubilization. The resulting solid dispersion, characterized by a rapid dissolution onset, provides a mean Cmax greater than 2 µg/ml at a 160 mg oral dose, with the Poloxamer content explicitly controlled to be less than 30% by weight of total lipophilic microphase-forming materials.

graph TD
    A[Crystalline Enzalutamide] --> B{Cryogenic Milling}
    B --> C[Amorphous Enzalutamide Powder]
    D[Poloxamer 407] --> E{Hot-Melt Extrusion}
    C --> E
    E --> F[Amorphous Solid Dispersion (ASD)]
    F --> G[Composition (Rapid-Dissolve Tablet)]
    G --> H{Oral Administration}
    H --> I[Rapid Cmax & Enhanced Bioavailability]

2. Operational Parameter Expansion

Derivative 2.1: Supercritical Fluid-Assisted Anti-Solvent Precipitation

Enabling Description:
A method for manufacturing a solid dispersion of enzalutamide and hydroxypropyl methylcellulose acetate succinate (HPMCAS-L grade) where enzalutamide is at least 60% amorphous and the dispersion contains less than 30% by weight of lipophilic microphase-forming materials. Enzalutamide and HPMCAS are co-dissolved in a suitable organic solvent (e.g., dimethyl sulfoxide, DMSO) to form a concentrated solution. This solution is then rapidly injected into a continuous flow of supercritical carbon dioxide (scCO2) at 40°C and 150 bar, acting as an anti-solvent. The rapid reduction in solvent power due to scCO2 induces immediate precipitation of an amorphous solid dispersion with controlled particle size (<10 µm). The scCO2 simultaneously extracts the organic solvent, resulting in a high-purity, solvent-free amorphous solid dispersion suitable for direct compression into tablets. This process ensures high amorphicity and fine particle size without thermal degradation.

graph TD
    A[Enzalutamide + HPMCAS-L] --> B{Dissolve in DMSO}
    B --> C[Solution A]
    D[Supercritical CO2 (40°C, 150 bar)] --> E{Anti-Solvent Precipitation Chamber}
    C --> E
    E --> F[Amorphous SDD (Microparticles)]
    F --> G{CO2 Separation & Solvent Recovery}
    G --> H[Dry Amorphous Solid Dispersion]
    H --> I[Further Processing (e.g., Tableting)]

Derivative 2.2: Continuous Twin-Screw Extrusion with Inline Analytics

Enabling Description:
A method for manufacturing a solid dispersion of enzalutamide (at least 60% amorphous) and a concentration-enhancing polymer (e.g., Soluplus®) using continuous twin-screw hot-melt extrusion. Powdered enzalutamide and Soluplus are gravimetrically fed into a twin-screw extruder. The extruder barrel temperature profile is precisely controlled (e.g., 140°C-180°C-170°C). Residence time in the extruder is maintained at approximately 45 seconds to ensure complete melting and mixing. An inline Near-Infrared (NIR) spectroscopic probe positioned at the die exit provides real-time monitoring of enzalutamide's amorphous content and dispersion homogeneity. Feedback control loops adjust extrusion parameters (e.g., screw speed, feeder rate) to maintain consistent product quality, ensuring >60% amorphous enzalutamide and a final product containing less than 30% by weight of lipophilic microphase-forming materials, thereby optimizing Cmax and AUC.

graph TD
    A[Enzalutamide Powder] --> B{Gravimetric Feeder}
    C[Soluplus Powder] --> B
    B --> D[Twin-Screw Extruder (Temp. Profile)]
    D --> E[Molten Mixture]
    E --> F{NIR Spectrometer (Inline)}
    F -- Real-time Amorphicity/Homogeneity --> G{Feedback Control System}
    G -- Adjusts Parameters --> B
    G -- Adjusts Parameters --> D
    F --> H[Extrudate (Solid Dispersion)]
    H --> I[Milling/Pelletizing]
    I --> J[Final Amorphous Solid Dispersion]

Derivative 2.3: Ultrasonic Atomization for Nano-Dispersion Formation

Enabling Description:
A method for manufacturing a solid dispersion of enzalutamide (at least 90% amorphous) and polyvinylpyrrolidone (PVP K30) where the dispersion contains less than 30% by weight of lipophilic microphase-forming materials. A solution of enzalutamide and PVP K30 (1:3 w/w ratio) in a volatile solvent like ethanol is prepared. This solution is fed to an ultrasonic nozzle operating at a frequency of 120 kHz, which generates extremely fine droplets (e.g., 5-20 µm diameter) at ambient temperature. These droplets are then subjected to gentle nitrogen gas flow in a drying chamber for rapid solvent evaporation, yielding a nano-sized amorphous solid dispersion powder. The low-temperature, fine-droplet formation minimizes thermal degradation and accelerates solvent removal, resulting in a highly amorphous and stable product with superior dissolution rates and expected Cmax/AUC values.

graph TD
    A[Enzalutamide + PVP K30] --> B{Dissolve in Ethanol}
    B --> C[Solution Feed]
    D[Ultrasonic Nozzle (120 kHz)] --> E[Ultra-fine Droplets]
    C --> D
    E --> F{Drying Chamber (Nitrogen Gas)}
    F --> G[Nano-sized Amorphous SDD]
    G --> H[Collection & Further Processing]
    H --> I[Enhanced Dissolution/Bioavailability]

3. Cross-Domain Application

Derivative 3.1: AgTech - Controlled Release Herbicide Formulation

Enabling Description:
A formulation for agricultural application comprising an amorphous solid dispersion of a poorly soluble herbicide (e.g., atrazine) and a plant-compatible polymer (e.g., lignin-based polymer or starch acetate). The herbicide, in an at least 60% amorphous state, is dispersed within the polymer matrix. This is achieved by co-dissolving the herbicide and polymer in a suitable solvent (e.g., ethyl acetate) and then spray-drying the solution. The resulting amorphous solid dispersion microparticles (e.g., 50-200 µm) are designed for improved foliar uptake and controlled release in agricultural environments, minimizing runoff and extending efficacy. This formulation delivers active ingredient to target weeds with enhanced bioavailability, mimicking the improved absorption observed for enzalutamide in human systems. Lipophilic additives are kept below 30% to maintain environmental compatibility.

graph TD
    A[Poorly Soluble Herbicide (API)] --> C{Co-dissolve in Solvent}
    B[Lignin-based Polymer] --> C
    C --> D[Herbicide-Polymer Solution]
    D --> E{Spray Drying}
    E --> F[Amorphous Herbicide Microparticles (SDD)]
    F --> G[Agrochemical Formulation (e.g., Liquid Suspension)]
    G --> H{Foliar/Soil Application}
    H --> I[Controlled Release & Enhanced Bioavailability in Plants]

Derivative 3.2: Veterinary Oncology - Palatable Tablet for Canine Prostate Cancer

Enabling Description:
A pharmaceutical composition for veterinary use, specifically treating canine prostate cancer, comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a veterinary-acceptable polymer (e.g., hydroxypropyl cellulose, HPC) combined with palatability enhancers (e.g., beef flavor, saccharin). Enzalutamide and HPC are co-dissolved in a common solvent and spray-dried to form the amorphous solid dispersion. This dispersion is then blended with flavorants and other excipients (e.g., microcrystalline cellulose, magnesium stearate) and directly compressed into palatable, chewable tablets of suitable size for large breed dogs (e.g., 100-300 mg enzalutamide per tablet). This formulation aims to improve enzalutamide's oral bioavailability in canines, leveraging the dissolution enhancement of the amorphous solid dispersion, thereby reducing the number of doses required and improving owner compliance, similar to the human therapeutic benefit. Lipophilic microphase-forming materials are maintained below 30% by weight.

graph TD
    A[Enzalutamide (API)] --> C{Dissolve & Spray Dry}
    B[HPC Polymer] --> C
    C --> D[Amorphous Enzalutamide SDD]
    E[Beef Flavor] --> F{Blend & Compress}
    G[Saccharin] --> F
    D --> F
    F --> H[Palatable Chewable Tablet]
    H --> I{Oral Administration to Canine}
    I --> J[Improved Bioavailability for Canine Cancer Treatment]

Derivative 3.3: Functional Coatings - UV-Protective Polymer Films

Enabling Description:
A polymer film for protective coatings comprising an amorphous solid dispersion of a poorly soluble organic UV-absorber (e.g., oxybenzone derivative) and a transparent polymer matrix (e.g., poly(methyl methacrylate), PMMA). The UV-absorber is rendered at least 60% amorphous by co-dissolving it with PMMA in a volatile solvent (e.g., toluene) and spray-coating this solution onto a substrate or casting it as a film. The amorphous dispersion provides enhanced molecular dispersion of the UV-absorber within the film, leading to improved transparency and more effective, uniform UV protection compared to crystalline forms. This technology finds application in durable exterior coatings, automotive finishes, or transparent packaging, leveraging the principle of enhanced molecular dispersion and stability of amorphous compounds in a polymer matrix. Lipophilic additives, if any, are kept below 30% by weight to maintain optical clarity and film integrity.

graph TD
    A[Poorly Soluble UV-Absorber] --> C{Co-dissolve in Toluene}
    B[PMMA Polymer] --> C
    C --> D[UV-Absorber-PMMA Solution]
    D --> E{Spray Coating/Film Casting}
    E --> F[Amorphous SDD within Polymer Film]
    F --> G[Cured UV-Protective Film]
    G --> H{Application (e.g., Automotive Coating)}
    H --> I[Enhanced & Uniform UV Protection]

4. Integration with Emerging Tech

Derivative 4.1: AI-Driven Formulation Optimization

Enabling Description:
A method for designing and manufacturing amorphous enzalutamide solid dispersions with optimal in vivo performance characteristics (AUC 0-7 days > 150 µg·hr/ml, Cmax > 2 µg·hr/ml) using an AI-driven optimization platform. The platform integrates a machine learning model trained on a large dataset of enzalutamide-polymer interactions, processing parameters (spray-drying, HME), and resulting in vitro dissolution/in vivo pharmacokinetic data. Users input desired target AUC/Cmax profiles and constraints (e.g., specific polymers, dosage form, manufacturing equipment limits). The AI algorithm predicts optimal polymer type(s), polymer:drug ratio, solvent system, and critical process parameters (e.g., inlet temperature, feed rate, screw speed, barrel temperature profile) to achieve the target performance while ensuring enzalutamide is at least 60% amorphous and lipophilic microphase-forming materials are below 30%. This system also suggests combinations with novel excipients and predicts their interaction.

graph TD
    A[Input: Target AUC/Cmax, Constraints] --> B{AI Optimization Platform}
    B --> C[Machine Learning Model]
    D[Historical Formulation Data] --> C
    E[Polymer-Drug Interaction Database] --> C
    C --> F[Predicted Optimal Formulation Parameters]
    F --> G[Manufacturing Process (e.g., Spray Drying)]
    G --> H[Amorphous Enzalutamide SDD]
    H --> I[Quality Control (Verify AUC/Cmax)]
    I -- Feedback Loop --> C

Derivative 4.2: IoT-Monitored Smart Packaging for Stability Assurance

Enabling Description:
A pharmaceutical dosage unit (e.g., tablet blister pack) containing an amorphous solid dispersion of enzalutamide (at least 60% amorphous) and HPMCAS, integrated with passive IoT sensors for real-time monitoring of environmental conditions and formulation stability. Each blister cavity or unit-dose pouch contains a miniature, wireless, non-invasive sensor that continuously records temperature and relative humidity. Data from these sensors is transmitted to a central gateway or smartphone app via low-power Bluetooth or NFC. An onboard micro-controller analyzes this data against pre-defined stability thresholds (e.g., critical humidity levels, excursions above glass transition temperature). Alerts are generated if conditions threaten the amorphous state of enzalutamide. This system ensures product integrity throughout the supply chain and at the patient's home, validating that the formulation retains its optimal AUC/Cmax characteristics and amorphous content. Data about environmental conditions is automatically stored, for example, on a blockchain.

graph TD
    A[Amorphous Enzalutamide SDD Tablet] --> B[Blister Pack / Unit-Dose Pouch]
    B --> C[Integrated IoT Sensor]
    C -- Temp/RH Data --> D{Wireless Gateway / Smartphone}
    D -- Data Stream --> E[Cloud Analytics Platform]
    E -- Alerts/Warnings --> F[Patient/Pharmacist App]
    E -- Stability Record --> G[Blockchain Ledger]
    G --> H[Immutable Audit Trail]
    subgraph Monitoring & Data Flow
        C --- D
        D --- E
    end

Derivative 4.3: Blockchain for Supply Chain & Authenticity Verification

Enabling Description:
A system for ensuring the authenticity and manufacturing provenance of amorphous enzalutamide solid dispersion pharmaceutical compositions (at least 60% amorphous, <30% lipophilic materials). Each batch of spray-dried or hot-melt extruded amorphous enzalutamide-polymer dispersion is assigned a unique batch identifier, cryptographically hashed, and recorded on a private blockchain ledger. Key manufacturing parameters (e.g., spray dryer inlet/outlet temperatures, solvent type, polymer:drug ratio, inline NIR amorphicity verification, final purity, packaging date) are also timestamped and recorded. Subsequent events like packaging, shipment, distribution to pharmacies, and dispensing are similarly recorded. Consumers or regulators can scan a QR code on the final dosage form, which queries the blockchain to verify its origin, manufacturing conditions, and confirm it corresponds to a genuine batch of the amorphous enzalutamide formulation, thereby mitigating counterfeiting and ensuring product quality (e.g., anticipated AUC/Cmax).

sequenceDiagram
    participant Manufacturer
    participant QC_Lab
    participant Distributor
    participant Pharmacy
    participant Patient
    participant Blockchain

    Manufacturer->>Blockchain: Record Batch ID & Mfg Params (Amorphicity, Polymer Ratio)
    QC_Lab->>Blockchain: Record Release Test Results (Purity, Dissolution, AUC/Cmax)
    Distributor->>Blockchain: Record Shipping & Logistics Data
    Pharmacy->>Blockchain: Record Receipt & Inventory Updates
    Patient->>Patient: Scan QR Code on Packaging
    Patient->>Blockchain: Query Batch ID for Authenticity
    Blockchain-->>Patient: Return Verified Mfg & Quality Data

5. The "Inverse" or Failure Mode

Derivative 5.1: Rapid Degrading Amorphous Dispersion for Environmental Safety

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a rapidly biodegradable, water-soluble polymer (e.g., polyethylene glycol-co-polycaprolactone, PEG-PCL, or specific grades of polylactide, PLA) designed for accelerated environmental degradation. The dispersion is manufactured via solvent evaporation, forming microparticles where enzalutamide is encapsulated. This formulation is engineered to provide therapeutic benefits upon oral administration (AUC 0-7 days > 150 µg·hr/ml) but, if inadvertently released into the environment (e.g., wastewater), the polymer matrix rapidly hydrolyzes under typical environmental conditions (e.g., soil pH, microbial activity), leading to accelerated degradation of both the polymer and enzalutamide into inert byproducts within days, rather than weeks or months. This minimizes ecological impact. Lipophilic microphase-forming materials are intentionally omitted or kept below 5% to facilitate rapid breakdown and reduce environmental persistence.

graph TD
    A[Enzalutamide] --> C{Co-dissolve in Solvent}
    B[PEG-PCL Polymer] --> C
    C --> D[Solution]
    D --> E{Solvent Evaporation/Microparticle Formation}
    E --> F[Rapidly Degrading Amorphous SDD]
    F --> G[Oral Administration (Therapeutic Effect)]
    G --> H{Environmental Release (Accidental)}
    H --> I[Rapid Polymer Hydrolysis]
    I --> J[Accelerated Enzalutamide Degradation]
    J --> K[Inert Byproducts (Environmental Safety)]

Derivative 5.2: Low-Dose, Limited-Functionality Formulation for Diagnostic Tracing

Enabling Description:
A pharmaceutical composition comprising a sub-therapeutic dose (e.g., 10 mg) of enzalutamide, where the enzalutamide is at least 60% amorphous, in a solid dispersion with a concentration-enhancing polymer (e.g., HPMC). This formulation is specifically designed for diagnostic purposes, such as tracing enzalutamide distribution or receptor occupancy via PET imaging (using a radiolabeled enzalutamide analog) or pharmacokinetic profiling in sensitive patient populations (e.g., early-stage clinical trials for dose ranging). The amorphous solid dispersion ensures rapid dissolution and absorption even at low doses, allowing for precise pharmacokinetic assessment without eliciting full therapeutic or adverse effects. The formulation deliberately avoids high drug loading or maximal concentration enhancement to operate in a "limited-functionality" mode, focusing on detection and distribution rather than full therapeutic impact. Lipophilic microphase-forming materials are less than 30% by weight.

graph TD
    A[Enzalutamide (Low Dose)] --> C{Co-dissolve & Spray Dry}
    B[HPMC Polymer] --> C
    C --> D[Low-Dose Amorphous SDD]
    D --> E[Diagnostic Capsule/Tablet]
    E --> F{Oral Administration (Diagnostic Use)}
    F --> G[Rapid Absorption for Tracing]
    G --> H[Imaging/Pharmacokinetic Profiling (Limited Therapeutic Effect)]

Derivative 5.3: Controlled Release with Triggered Fail-Safe Excretion

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a concentration-enhancing polymer (e.g., HPMCAS), further encapsulated within an enteric-coated system that includes an excipient designed for triggered rapid excretion. The enzalutamide-polymer dispersion provides the desired AUC/Cmax upon normal gastrointestinal transit. However, in the event of accidental overdose or adverse reaction, administration of a specific counter-agent (e.g., a high-pH solution or a chelating agent) triggers the rapid disintegration of the enteric coating and/or the polymer matrix, leading to rapid and controlled release of enzalutamide into the intestinal lumen, followed by accelerated fecal excretion through the action of a co-formulated, mild, non-toxic laxative agent (e.g., magnesium citrate, PEG 3350) incorporated into the outer layer. This "fail-safe" mechanism reduces systemic exposure in emergency situations. Lipophilic microphase-forming materials are kept below 30%.

stateDiagram
    [*] --> Formulated_SDD
    Formulated_SDD --> In_Digestive_Tract : Oral Administration
    In_Digestive_Tract --> Therapeutic_Release : Normal Transit (Optimal AUC/Cmax)
    In_Digestive_Tract --> Fail_Safe_Mode : Accidental Overdose / Adverse Event
    Fail_Safe_Mode --> Trigger_Administered : Counter-Agent (e.g., High pH Solution)
    Trigger_Administered --> Rapid_Disintegration : Enteric Coat & Matrix Breakdown
    Rapid_Disintegration --> Accelerated_Excretion : Enhanced Fecal Clearance
    Accelerated_Excretion --> [*]

---

Combination Prior Art Scenarios

These scenarios combine the teachings of US Patent 12447128 with existing open-source standards or widely available knowledge, rendering specific applications or refinements obvious.

1. US12447128 + ICH Q8/Q9/Q10 (Quality by Design Guidelines):
   A person skilled in the art, following the principles of Quality by Design (QbD) as outlined in ICH guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System), would find it obvious to apply a systematic approach to optimize the manufacturing process (Claim 11) for amorphous enzalutamide solid dispersions. This would involve using a Design of Experiments (DoE) approach to identify critical process parameters (CPPs) for spray-drying (e.g., inlet/outlet temperatures, feed rate, atomization pressure) and critical material attributes (CMAs) for enzalutamide and the polymer (e.g., particle size, molecular weight, crystallinity), to achieve a predefined target product profile (TPP) for the resulting amorphous solid dispersion. The use of Process Analytical Technology (PAT) tools (e.g., inline NIR for amorphicity, particle size distribution, moisture content) would be routinely implemented to monitor and control these CPPs in real-time, ensuring consistent quality, including the desired amorphous content (>60%) and dissolution performance (MDC, AUC), as well as controlling lipophilic microphase-forming materials (<30%).

2. US12447128 + Open-source Population PK/PD Modeling (e.g., NONMEM, R-packages like 'mrgsolve'):
   It would be obvious to a person skilled in the art to use established population pharmacokinetic/pharmacodynamic (PK/PD) modeling techniques, readily available through open-source software (e.g., NONMEM, or R-packages such as 'mrgsolve' and 'nlmixr'), to refine and predict the in vivo performance (AUC 0-7 days > 150 µg·hr/ml, Cmax > 2 µg/ml) of amorphous enzalutamide solid dispersions (Claims 1 & 17). This involves collecting sparse or full PK data from initial human studies (e.g., those described in Example 15 of US12447128), fitting these data to population PK models, and then using simulations to predict optimal dosing regimens, inter-patient variability, and the impact of formulation changes (e.g., different polymer ratios, particle sizes of the amorphous dispersion) on systemic exposure and therapeutic outcomes. This approach allows for efficient prediction of desired in vivo characteristics without extensive clinical trials for every formulation variant.

3. US12447128 + Open-source Computational Chemistry & Materials Science Libraries (e.g., LAMMPS, RDKit, MDAnalysis):
   Given the understanding of amorphous solid dispersions for improving solubility, a person skilled in the art would find it obvious to utilize open-source computational chemistry and materials science tools to predict and optimize the stability and performance of enzalutamide-polymer amorphous solid dispersions (Claims 1 & 17). Specifically, molecular dynamics (MD) simulations using software like LAMMPS (Large-scale Atomic/Molecular Massively Parallel Simulator) could be employed to model the drug-polymer interactions at an atomic level, predicting glass transition temperatures (Tg), miscibility, and potential for recrystallization. Cheminformatics libraries like RDKit could be used to screen a vast array of potential concentration-enhancing polymers based on predicted compatibility with enzalutamide's chemical structure. This computational approach would accelerate the selection of optimal polymers and formulation parameters, reducing the need for extensive empirical testing to achieve stable amorphous forms, desired AUC/Cmax, and maintain the low content of lipophilic microphase-forming materials.